Abstract Alzheimer's disease (AD), the most common form of dementia, remains challenging
to understand and treat despite decades of research and clinical investigation. This might be …

Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations
with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p …

I read with interest the insightful article by Gonzalez-Ortiz et al. 1 regarding the development
of a new assay for quantification of phosphorylated threonine 217 tau (pT217-tau) in the …

The glucagon-like peptide-1 receptor (GLP-1R) agonists reduce glycated hemoglobin in
patients with type 2 diabetes. Mounting evidence indicates that the potential of GLP-1R …

Accurate differential diagnosis of dementia disorders including Alzheimer disease (AD),
frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), Parkinson disease …

Alzheimer's disease (AD) represents a growing global health challenge, necessitating
accurate and reliable diagnostic methodologies for timely intervention and management …

Importance: Detecting early Alzheimers disease (AD) biological and clinical changes is
crucial for early diagnostic and therapeutic interventions. Objective: To explore the …

Background Among plasma biomarkers for Alzheimer's disease (AD), pTau181 and
pTau217 are the most promising. However, transition from research to routine clinical use …

Importance: Positron emission tomography (PET) biomarkers are the gold standard for
detection of Alzheimer amyloid and tau in vivo. Such imaging can identify cognitively …

INTRODUCTION Tau aggregation into paired helical filaments and neurofibrillary tangles is
characteristic of Alzheimer's disease (AD) and related disorders. However, biochemical …